Transmitter amines in depression

Curzon, G.

doi:10.1017/s0033291700055562

Cited by 15 publications

(3 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite its limitations CSF monoamine metabolite measurements supply information about metabolism and turnover of the respective transmitter amine (Curzon, 1976;van Praag, 1980). In man this is the least indirect method to study the central metabolic events in vivo; some of the drawbacks of this technique can be avoided by simultaneous measurement of more than one substance in the CSF samples, and by measuring not only the metabolites but also their precursors.…”

Section: Introductionmentioning

confidence: 99%

Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence

Bánki¹

1981

J. Neural Transmission

103

View full text Add to dashboard Cite

Cerebrospinal fluid 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA) and tryptophan (TRY) were measured in 36 female patients with alcohol dependence defined by strict operational criteria. Results were compared with a control group of 32 women hospitalized in a neurological unit for peripheral diseases. Several disorders presumably interfering with monoamine metabolism were excluded and diet, psychomotor activity, diurnal variation, nutritional state and similar nonspecific variables controlled in both groups. Only 5-HIAA was found to be decreased in development patients as compared to controls. Since 5-HIAA--but neither HVA nor TRY--correlated with body height in both groups, we eliminated its effect by analysis of covariance: as a result 5-HIAA difference became statistically significant but the other two biochemical measures remained unchanged. A multivariate regression analysis with five independent clinical variables (body height, age, weight, years of alcohol abuse and days of abstinence) yielded significant determination coefficient R2 only for 5-HIAA. Regarding its components only body height and days of abstinence proved to be significantly correlated with 5-HIAA. Severity of withdrawal symptoms assessed on a rating scale in 14 patients with 4 days or less of abstinence correlated marginally with HVA but not with 5-HIAA. This latter metabolite decreased only in patients with 5 days or more of abstinence; the difference between 5-HIAA levels of short-term and long-term abstinence subgroups was statistically highly significant.

show abstract

Section: Introductionmentioning

confidence: 99%

Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence

Bánki¹

1981

J. Neural Transmission

103

View full text Add to dashboard Cite

show abstract

“…O papel da serotonina na gênese dos estados depressivos foi primeiramente postulado há cerca de 40 anos (Lapin e Oxenkrug, 1969). Desde essa época, inúmeros estudos com modelos animais de depressão, estudos clínicos com pacientes deprimidos, estudos com depleção de serotonina e mesmo estudos post-mortem têm dado suporte a essa hipótese (Curzon, 1982;Delgado et al, 1999).…”

Section: Artigo Original Introduçãounclassified

Fluvoxamina no transtorno depressivo maior: um estudo multicêntrico aberto

Porto

Mello

Kerr-Corrêa

et al. 2007

J. bras. psiquiatr.

View full text Add to dashboard Cite

OBJETIVO: Este trabalho estudou a eficácia e a tolerabilidade da fluvoxamina no tratamento, de forma aberta, sem comparação com placebo ou outros agentes, por 6 semanas, de pacientes com o diagnóstico de transtorno depressivo maior (TDM). Constitui-se em objetivo secundário do estudo avaliar os efeitos da fluvoxamina sobre o sono dos pacientes. MÉTODOS: Foram incluídos 104 pacientes, maiores de 18 anos, com o diagnóstico de TDM, de acordo com os critérios do Manual Diagnóstico e Estatístico de Transtornos Mentais, 4ª edição (DSM-IV), e com escores, na Escala de Hamilton para Depressão, versão de 17 itens (HAM-D 17), de 17 pontos ou mais. Avaliou-se a eficácia da fluvoxamina por meio das Escalas HAM-D 17 e da CGI (Impressão Clínica Global). A análise dos itens 4, 5 e 6 da HAM-D 17 foi utilizada para a avaliação do sono dos pacientes. Avaliaram-se a segurança e a tolerabilidade da fluvoxamina ao longo das 6 semanas, registrando-se quaisquer eventos adversos. A fluvoxamina foi inicialmente ministrada em doses de 50 ou 100 mg/dia, podendo haver aumentos progressivos até 300 mg/dia. RESULTADOS: Dos 104 pacientes incluídos, 81 (78%) concluíram o estudo. Obtiveram resposta favorável (diminuição de 50% ou mais na HAM-D 17) 69% dos pacientes, e a taxa de remissão (HAM-D 17 < 7) foi de 52%. A análise da CGI indicou ter havido melhora significante (p < 0,001) em relação aos escores de base. A análise específica dos itens relativos ao sono, na HAM-D 17, revelou melhora significativa já na segunda visita, mantendo-se ao longo das 6 semanas. Os eventos adversos foram os esperados para inibidores seletivos de recaptação da serotonina, predominando as queixas gastrointestinais, em sua maioria transitórias e de pequena intensidade. CONCLUSÃO: O estudo vem confirmar a eficácia e a tolerabilidade da fluvoxamina no tratamento do transtorno depressivo maior, assim como sua eficácia no tratamento das alterações do sono encontradas nos pacientes deprimidos. O perfil de eventos adversos foi o esperado para os ISRS, ressaltando-se o fato de que poucos pacientes relataram disfunção sexual (2,5% dos pacientes).

show abstract

“…During recent years there has been an increasing interest in studies on the development of secondary effects due to drugs which affect the transmitter amines 5-hydroxytryptamine (5-HT), dopamine, and noradrenaline in the brain (for review see Curzon, 1982;Sugrue, 1983). Such secondary effects, e.g.…”

Section: Introductionmentioning

confidence: 99%

The effect of selective 5‐hydroxytryptamine uptake inhibitors on 5‐methoxy‐N,N‐dimethyltryptamine‐induced ejaculation in the rat

Rènyi

1986

British J Pharmacology

View full text Add to dashboard Cite

1The ejaculatory response and the 5-hydroxytryptamine (5-HT) behavioural syndrome induced by 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) (3 mg kg-' i.p.) were studied following acute and repeated treatment of rats with the selective uptake inhibitors of 5-HT, fluoxetine, zimeldine, alaproclate, and citalopram. The oral doses used were based on the respective EDM values for uptake inhibition. 2 Acute doses of fluoxetine and zimeldine significantly reduced the ejaculatory response when given 48 h before 5-MeODMT. This blockade was prevented by treatment ofthe rats with the postsynaptic 5-HT receptor antagonist methergoline. 3 An acute dose of fluoxetine given 7 and 14 days before 5-MeODMT significantly enhanced the ejaculatory response. On day 24, the response returned to the control level. Repeated treatment every second day (5 times over 9 days and 10 times over 19 days) with fluoxetine caused a longer blockade of the ejaculatory response and the sensitization of the response came later than after an acute dose. Parallel with the ejaculatory response three other components of the 5-HT behavioural syndrome also decreased significantly. 4 Acute doses ofalaproclate and citalopram significantly blocked the ejaculatory response at I h, but they failed to affect the response at any other time point after either acute or repeated treatment. Neither did these drugs attentuate the 5-HT syndrome. 5 It is concluded that acute and repeated treatment of rats with different selective 5-HT uptake inhibitors does not produce a common alteration in 5-HT2-receptor functions.

show abstract

Transmitter amines in depression

Cited by 15 publications

References 62 publications

Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence

Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence

Fluvoxamina no transtorno depressivo maior: um estudo multicêntrico aberto

The effect of selective 5‐hydroxytryptamine uptake inhibitors on 5‐methoxy‐N,N‐dimethyltryptamine‐induced ejaculation in the rat

Contact Info

Product

Resources

About